Clinical Trial Update: Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 study is evaluating postoperative radiotherapy plus Nimotuzumab followed by Benmelstobart in high-risk head and neck squamous cell carcinoma, and the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Benmelstobart
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer | Phase 3 | Status: RECRUITING